Pafuramidine

Drug Profile

Pafuramidine

Alternative Names: DB-289; Parfuramidine maleate

Latest Information Update: 28 Aug 2014

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Georgia State University; University of North Carolina at Chapel Hill
  • Developer CombinatoRx; Immtech Pharmaceuticals
  • Class Antiparasitics; Benzamidines; Small molecules
  • Mechanism of Action DNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pneumocystis pneumonia; Malaria; Trypanosomiasis

Highest Development Phases

  • Discontinued Cancer; Malaria; Pneumocystis pneumonia; Trypanosomiasis

Most Recent Events

  • 01 Aug 2014 TopoTarget has merged with BioAlliance Pharma to form Onxeo SA
  • 22 Feb 2008 Immtech Pharmaceuticals has discontinued all development programmes for pafuramidine in response to additional adverse events identified in a cohort of subjects in a safety study of the drug
  • 26 Dec 2007 Suspended - Phase-II for Malaria prevention in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top